TG Therapeutics, Inc.

NASDAQ:TGTX

Biotechnology

Healthcare
$66.12 +2.00%

+$1.03 today

Market cap
$9.99B
Beta
1.68
P/E (TTM)
16.4
EPS (TTM)
$3.20
52W Low $25.28High $53.98

Volume 1.87M

Average 2.15M

TGTX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

TG Therapeutics, Inc.NASDAQ: TGTX

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 57.1% from a year ago

Net receivables stood at $416.82M at the end of Q3 FY2026, up 57.1% from a year earlier and up 3.8% from the prior quarter.

Context

  • Net receivables amounted to 26.2% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +57.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$416.82M+3.8% QoQ
Last fiscal yearDec 2025
$305.63M+136.6% YoY
Year agoSep 2025
$265.38M+57.1% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.1%——
1 year+136.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
305.63M USD
Year-over-year change
+136.6%
4-year CAGR
+285.1%

Net Receivables vs competitors

How TGTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +57.1% is the 5th highest of 9, against a peer median of +68.5%.
  • Net receivables amounts to 26.2% of total assets for TGTX, versus a peer median of 5.3%.
TGTX Competitors
Net Receivables for TGTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
GMABGenmab A/SJun 2026$1.28B USD+28.3%-41.4%10.2%
TGTXTG Therapeutics, Inc.Sep 2026$416.82M USD+57.1%—26.2%
XNCRXencor, Inc.Jun 2026$42.23M USD-11.2%+0.3%5.8%
ADCTADC Therapeutics S.A.Mar 2026$31.05M USD-2.3%-26.4%10.7%
MGNXMacroGenics, Inc.Mar 2026$10.43M USD-1.1%-38.0%4.8%
IPHAInnate Pharma S.A.Dec 2025€7.61M EUR+363.2%+34.3%12.1%
CRVSCorvus Pharmaceuticals, Inc.Mar 2026$1.2M USD+427.8%-16.1%0.5%
CLDXCelldex Therapeutics, Inc.Sep 2026$355K USD+294.4%+79.7%0.0%
ADAGAdagene Inc.Dec 2025$17.35K USD+108.8%-69.6%0.0%
Peer median (excluding TGTX) —+68.5%-21.2%5.3%

Competitors are the stored peer set for TGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents298.89M102.3M92.93M179.89M79.15M
Short-term Investments15.88M59.37M124.58M131.11M62.82M
Net Receivables1.39M051.09M129.19M305.63M
Inventory0039.82M110.46M125.59M
Other Current Assets2.88M2.36M5.34M15.72M57.58M
Total Current Assets330.97M168.27M317.94M566.36M630.76M
Property, Plant & Equipment (Net)11.07M10.82M8.15M7.15M6.28M
Goodwill799K799K799K00
Intangible Assets00000
Long-term Investments35.53M12.4M1.29M808K59.14M
Tax Assets0000348M
Other Non-current Assets1.26M1.27M1.42M3.37M19.08M
Total Non-current Assets48.66M25.3M11.64M11.33M432.49M
Total Assets379.63M193.57M329.59M577.69M1.06B
Account Payables0000107.51M
Short-term Debt975K0001.04M
Tax Payables00000
Deferred Revenue00152K11.41M21.23M
Other Current Liabilities62.97M51.62M52.12M78.11M23.97M
Total Current Liabilities65.38M53.2M53.72M90.68M153.76M
Long-term Debt66.79M71.14M100.12M244.43M252.67M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)457K305K6.02M12.09M8.81M
Other Non-current Liabilities0000(7.02M)
Total Non-current Liabilities77.09M81.78M115.37M264.65M261.47M
Total Liabilities142.48M134.99M169.09M355.33M415.23M
Common Stock143K146K151K156K159K
Retained Earnings(1.33B)(1.53B)(1.55B)(1.53B)(1.08B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity237.15M58.59M160.5M222.36M648.02M
Total Debt79.05M83.06M110.8M253.72M260.73M
Net Debt(219.84M)(19.24M)17.86M73.83M181.58M

TG Therapeutics, Inc.

NASDAQ:TGTX

Intrinsic Alpha fair value

Locked

Current Price

$66.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.